



Reducing the chance of relapse in vaginal candidosis

When *Candida* plays hide and seek

Recent microscopy studies have shown that *Candida albicans* appears capable of penetrating the deeper keratinous layers of vaginal epithelial cells. This suggests that the organisms may be protected from topical antifungal agents, only to re-emerge and proliferate again some time later when the epithelial cells are normally shed.

As the deeper layers of the vaginal mucosa are reached more easily by systemic than by topical treatment, relapse is likely to be avoided accordingly.

Scanning electron micrograph
of mycelial cells penetrating
between vaginal surface
epithelial cells. (x 3000)

TRADEMARK
Nizoral
ketoconazole

*The elegant way
to treat an inelegant problem*

Presentation: white, flat, half-scored uncoated tablets marked "Janssen" on one side and K/200 on the reverse. Each tablet contains 200 mg ketoconazole. Dosage (for vaginal candidosis only): two tablets (400 mg) once daily for 5 days. For maximal absorption Nizoral should be taken with meals. Nizoral is contra-indicated in pregnancy. Precautions: the use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H₂-blockers) should be avoided and, if indicated, such drugs should be taken not less than 2 hours after Nizoral. Ketoconazole, when given together with cyclosporin A results in increased blood levels of cyclosporin A. It is important that blood levels of cyclosporin A are monitored if the two drugs are given concomitantly. Side-effects: nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole; these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped. Mild asymptomatic increases of liver enzyme levels, on the other hand, do not necessitate discontinuation of the treatment.

Full prescribing information available on request.
Ref.: Acta Cytol. (Baltimore) 26, 7 (1982)



JANSSEN

PHARMACEUTICA

B-2340 Beerse, Belgium

world leader in antimycotic research

PUBLICATION DATE 26 AUGUST 1987

Second revised
expanded edition

ABC OF ONE TO SEVEN

H B VALMAN

Practice rather than theory is the keynote of the *ABC of One to Seven* in its straightforward advice on the diseases, emotional problems, and developmental disorders of early childhood. This has now been amplified in a second edition which contains new chapters on recurrent headache and child abuse as well as extensive revisions of chapters on sleep problems, bronchial asthma, and primary and community care. The *ABC of One to Seven* has already become the standard guide for general practitioners, medical students, vocational trainees, and clinical medical officers. The second, revised and expanded edition brings it fully up to date.

Price: Inland £8.95
Overseas £11.00/USA\$19.00
(Inland £7.95;
Overseas £10.00/USA\$17.50
to BMA members)

Despatched by air overseas

Payment must be enclosed with order

ABC OF ONE TO SEVEN



Reviews of the first edition . . .

"... the great merit of this book, as with the original articles, is that the common paediatric problems as they present to a general practitioner or a hospital clinic are dealt with by an experienced paediatrician who is also an experienced writer."

Postgrad Med J 1983; 59: 273

"... an interesting, informative and well-illustrated guide to some of the difficulties encountered in the treatment of young children . . . the principles expressed are excellent, the format and content eminently digestible and the price reasonable."

Med J Aust 1983; 1: 390

Order from BRITISH MEDICAL JOURNAL, PO Box 295
London WC1H 9JR or any leading bookseller

BRITISH MEDICAL JOURNAL
EUROPEAN ASSOCIATION OF SCIENCE EDITORS

**EDITING A MEDICAL JOURNAL:
a workshop for editors of medical journals**

to be held at
The Spa Hotel
Tunbridge Wells, Kent
on
12-13 November 1987

PROVISIONAL PROGRAMME

Thursday 12 November 1987

- 1530 Tea
- 1600 Introduction
- 1615 What should be done about false references? (Ms D Mundy)
- 1715 Electronic journals, with demonstration (Dr N Paskin, Professor P Quilliam)
- 1900 Dinner

Friday 13 November 1987

- 0900 Workshops*
- 1000 Coffee
- 1020 English as an international language (Professor C Rümke)
- 1120 Workshops*
- 1220 Lunch
- 1400 Standard abstracts (Dr J Sinclair)

** On book reviews, keeping track of manuscripts, and how prescriptive editors should be.*

The fee of £100 (£95 for members of EASE and the BMA) will include a single room and all meals. The day rate for those wishing to attend only on Friday is £45 (£40 for members of EASE and the BMA).

The number of places is limited, and applications, including the fee (cheques made payable to the British Medical Journal), should be sent as soon as possible to the Editor, British Medical Journal, BMA House, Tavistock Square, London WC1H 9JR.

Rocephin

ceftriaxone


Trade Mark

24-hour bactericidal power

Once daily
parenteral cephalosporin

Highly effective in a broad range of pathogens

Neisseria meningitidis
(human blood agar)




MIC₅₀: $\leq 0.008 \mu\text{g/ml}$
MIC₉₀: $\leq 0.008 \mu\text{g/ml}$

Proteus mirabilis
(maltose agar)



MIC₅₀: $0.008 \mu\text{g/ml}$
MIC₉₀: $0.025 \mu\text{g/ml}$

Salmonella typhimuricum
(S.S. agar)




MIC₅₀: $0.007 \mu\text{g/ml}$
MIC₉₀: $0.125 \mu\text{g/ml}$

Klebsiella pneumoniae
(endo agar)



MIC₅₀: $0.05 \mu\text{g/ml}$
MIC₉₀: $0.1 \mu\text{g/ml}$

Escherichia coli
(Levine EMB agar)



MIC₅₀: $0.05 \mu\text{g/ml}$
MIC₉₀: $0.1 \mu\text{g/ml}$

sensitive: $\leq 8 \mu\text{g/ml}$; intermediate: $16-32 \mu\text{g/ml}$

Reference

1. Data on file,
F. Hoffmann-La Roche & Co. Limited Company,
Basle, Switzerland.



F. Hoffmann-La Roche & Co.
Limited Company, Basle, Switzerland

GOOD DRUGS DON'T GROW ON TREES

*In the prehistoric days of medicine
some drugs could be found
growing on trees.*

Today that's a bit different.

*The therapeutic drugs of our times
are being unmasked from nature
rather more scientifically.*

*By thorough bio-medical research
into the fundamental processes of life.
By studying exactly why and how
these processes sometimes go wrong.*

*And so nature shows man where and how
he can intervene and defend himself.*

*With precision drugs that will selectively
and safely correct what went wrong.*

*Today's drugs grow from man's scientific
knowledge of nature —
but no longer on trees.*